Considering the prolonged preclinical period preceding AD onset, identifying the earliest APOE-dependent neurodegenerative changes may provide a window of opportunity for timely detection at critical points along the disease course, warranting focus on asymptomatic individuals. The gene discussed is APOE; the disease is Alzheimer disease.